학술논문
Significant improvement of a nevus spilus-type congenital melanocytic nevus with oral selumetinib.
Document Type
Editorial & Opinion
Author
Berna R; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Hasbun T; Dermatology Department, Clínica Alemana de Santiago - Facultad de Medicina Universidad del Desarrollo and Hospital Exequiel González Cortés, Santiago, Chile.; Adams D; Division of General Pediatrics, Section of Pediatric Hematology and Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Moon AT; Division of General Pediatrics, Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Treat JR; Division of General Pediatrics, Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Source
Publisher: Wiley Country of Publication: United States NLM ID: 8406799 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1470 (Electronic) Linking ISSN: 07368046 NLM ISO Abbreviation: Pediatr Dermatol Subsets: MEDLINE
Subject
Language
English
Abstract
Giant congenital melanocytic nevi (GCMN) can be cosmetically significant and can lead to melanoma. There is no standard pharmacologic treatment for GCMN. We present the case of an 8-year-old female with kaposiform lymphangiomatosis caused by an NRAS mutation whose nevus spilus-type GCMN improved on oral selumetinib.
(© 2024 The Author(s). Pediatric Dermatology published by Wiley Periodicals LLC.)
(© 2024 The Author(s). Pediatric Dermatology published by Wiley Periodicals LLC.)